The revenue growth is overshadowed by a widening net loss and going-concern risk. Monitor for any financing or partnership announcements that could alleviate cash burn, as the stock is highly speculative at a $3M market cap.
Price Chart
Executive Summary
Sixty Degrees Pharmaceuticals reported Q2 2026 revenue of $208K (up 106% YoY) but a net loss of $2.40M ($0.90/share), missing the consensus EPS estimate of -$0.89 by 1.1%. The company highlighted a going-concern risk and high operating expenses, making this a bearish filing for a micro-cap biotech with no clear path to profitability.
Key Financial Metrics
Key Facts
- Net product revenue increased 106% YoY to $208K in Q2 2026 from $101K in Q2 2025.
- Net loss attributable to common stockholders was $2.40M ($0.90/share) vs $1.84M ($5.01/share) in Q2 2025.
- EPS of -$0.90 missed consensus estimate of -$0.89 by 1.1%.
- Operating expenses rose to $2.33M from $1.86M YoY.
- Company notes substantial doubt about its ability to continue as a going concern.
Financial Impact
Revenue growth of 106% YoY to $208K, but net loss widened to $2.40M with EPS miss of 1.1% vs consensus.
Risk Factors
- Going-concern risk explicitly stated; company may need to raise capital or face delisting.
- High operating expenses relative to revenue; no clear path to profitability.
- Micro-cap biotech with low liquidity; stock price highly volatile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers